Elusys Therapeutics is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious diseases. The Company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim, for the prophylaxis and treatment of anthrax disease following a biowarfare attack.
Elusys Therapeutics asked Ten Six to support an existing Deltek MPM implementation and user base. Deltek MPM was being used to support a 5-year project but was struggling to provide it’s customer with robust Earned Value Management (EVM) data.
Ten Six Approach
Our approach centered around personalized support through one-on-one mentoring and coaching. In addition, training in Deltek MPM and EVM concepts was required at all levels within the organization from senior management EVM awareness to interactive hands-on MPM training. Specific deliverables included:
- EVM awareness workshops for senior management.
- Detailed EVM training classes for the program controls staff.
- Training in Deltek’s MPM tool with live data input, analysis and review. This included:
- Using the inputs of monthly report data.
- A review of cumulative schedule, performance, actual, and baseline inputs.
Ongoing support was also provided to ensure the live and accurate production of monthly reports. This entailed a review of the monthly reports and a comprehensive debrief with Elusys management.
Elusys successfully completed their monthly reporting cycles with accurate data showing project performance. Ten Six was able to complete all work within the planned timeframes and budget. Knowledge transfer was achieved with a combination of both one-on-one training, mentoring and coaching, working with real project data and thorough documentation including desktop process guides to support the EVMS process.